Article thumbnail
Location of Repository

Tolerance Induction to Cytoplasmic β-Galactosidase by Hepatic AAV Gene Transfer — Implications for Antigen Presentation and Immunotoxicity

By Ashley T. Martino, Sushrusha Nayak, Brad E. Hoffman, Mario Cooper, Gongxian Liao, David M. Markusic, Barry J. Byrne, Cox Terhorst and Roland W. Herzog
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1992). Adenovirus-mediated in vivo gene transfer and expression in normal rat liver.
  2. (1993). Assessment of recombinant adenoviral vectors for hepatic gene therapy.
  3. (2006). Cellular and molecular mechanisms of liver tolerance.
  4. (1995). Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo.
  5. (2007). Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse.
  6. (1999). Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
  7. (2008). Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs.
  8. (1997). Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice.
  9. (1996). Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70: 8098–8108. 6 . K e s s l e rP D ,P o d s a k o f fG
  10. (2007). Emerging role of regulatory T cells in gene transfer.
  11. (2006). Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer.
  12. (2007). Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.
  13. (2006). Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.
  14. (2001). Factors influencing crosspresentation of non-self antigens expressed from recombinant adeno-associated virus vectors.
  15. (2006). Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease.
  16. (2009). Hepatic gene transfer as a means of tolerance induction to transgene products.
  17. (1997). Identification of a Kbrestricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for ‘‘self’’ antigens.
  18. (2007). Immune responses to gene product of inducible promoters.
  19. (1996). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirusinfected hepatocytes in vivo.
  20. (1996). Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle.
  21. (2005). Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II.
  22. (2009). Improved Induction of Immune Tolerance to Factor IX by Hepatic AAV-8 Gene Transfer. Hum Gene Ther, in press.
  23. (2007). Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer.
  24. (2004). Induction of antigen-specific CD4+ T cell anergy and deletion by in vivo viral gene transfer.
  25. (2003). Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.
  26. (2007). Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products.
  27. (2005). Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
  28. (2007). Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver.
  29. (2007). Muscle as a Target for Supplementary Factor IX Gene Transfer.
  30. (2003). Optimized production of high-titer recombinant adeno-associated virus in roller bottles.
  31. (2006). Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.
  32. (1997). Recombinant adeno-associated virus for muscle directed gene therapy.
  33. (2005). Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves longterm correction of hemophilia B in a large animal model.
  34. (2007). Regulatory T cells dynamically control the primary immune response to foreign antigen.
  35. (2002). Role of primary intrahepatic T-cell activation in the ‘liver tolerance effect’.
  36. (2000). Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
  37. (2000). Route of administration determines induction of T-cell-independent humoral responses to adeno-associated virus vectors.
  38. (1997). Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.
  39. (1996). Successful expression of human factor IX following repeat administration of adenoviral vector in mice.
  40. (2008). The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response.
  41. (2004). The innate immune response to adenovirus vectors.
  42. (2005). Tolerance induction by viral in vivo gene transfer.
  43. (1998). Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers.
  44. (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial.
  45. (1995). Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cellmediated elimination of recombinant adenovirus-infected hepatocytes in vivo.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.